Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering

Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering

Abstract Background Mesothelin is a 40 kDa glycoprotein overexpressed in several cancers, including triple-negative breast cancer (TNBC). The anti-mesothelin single-domain antibody (sdAb, or nanobody) A1 can serve as a radio-theranostic agent, but random DOTA conjugation on lysines yields heterogene...

Full description

Saved in:
Bibliographic Details
Main Authors: Émilien N’Guessan, Florian Raes, Mitra Ahmadi, Sandrine Bacot, Laurent Dumas, Julien Leenhardt, Marlène Debiossat, Clémence André, Jean-Luc Lenormand, Catherine Ghezzi, Daniel Fagret, Charlotte Lombardi, Alexis Broisat
Format: Article
Language:English
Published: SpringerOpen 2025-04-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Site-specific radiolabeling
sdAb
Mesothelin
Theranostic
Kidney retention
Online Access:https://doi.org/10.1186/s41181-025-00340-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41181-025-00340-z

Similar Items